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Calvin B. Williams3 and Sam T. Hwang1
Macrophages have key roles in tumor development and invasion in several human cancers, but little is known
about their pathogenic role in cutaneous T-cell lymphoma (CTCL). Herein, we used PCR arrays to profile the
expression of inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of
CTCL. Compared with normal controls, MF skin displayed increased mRNA levels of macrophage-related
cytokines. Moreover, we detected CD163, a reliable marker of tumor-associated macrophages, in the tumor
microenvironment of MF biopsies. To demonstrate that macrophages had a role in CTCL tumorigenesis, we
xenografted human CTCL tumor cells in immunocompromised mice and compared tumor development using
clodronate-containing liposomes to deplete macrophages in mice. Mice treated with clodronate-containing
liposomes show markedly less tumor growth compared with mice treated with phosphate-buffered saline-
containing liposomes (Po0.001). We also noted a strong correlation between macrophage depletion and
decreased expression of vascular marker, CD31, and lymphatic marker, podoplanin, suggesting a role for
macrophages in angiogenesis. In vitro, clodronate-containing liposomes killed activated murine M2 macro-
phages, but not Hut78 cells, demonstrating selective ability to induce apoptosis in macrophages. Our data
indicate that macrophages have a critical role in the progression of Hut78 cell tumor formation in skin, thus
providing a new therapeutic strategy for CTCL.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group
of rare non-Hodgkin’s lymphomas that characteristically
involve the skin as the principle site of neoplastic T-cell
proliferation (Hwang et al., 2008). Mycosis fungoides (MF) is
the most common type of CTCL. In its early stage, patches of
eczematous skin showing mild-moderate redness and scaling
in non-sun-exposed locations are characteristic of the disease.
Later stages of disease are associated with increased
induration of the skin with neoplastic T cells (plaque stage)
and formation of massively thickened tumors comprising
malignant T cells (tumor stage) with associated inflammatory
cells and tumor stroma. Although it has long been established
that the malignant T cells of MF are predominantly clonal
CD4þ T cells (Hwang et al., 2008), recent data indicate that
these cells are likely derived from long-lived, skin-resident
T cells (Campbell et al., 2010).
Tumor-promoting inflammation has been postulated to be an
additional key component of cancer development (Hanahan
and Weinberg, 2011). Macrophages have long been associated
with the tumor microenvironment of a diverse subset of solid
cancers (Mantovani et al., 2004). These so-called tumor-
associated macrophages (TAMs) possess many, although not
necessarily all, of the features of macrophages cultured in vitro
in the presence of the T helper type 2 (Th2) cytokines IL-4 and
IL-13 (classic M2 macrophages). The role of macrophages in
lymphoma, however, has not been as well established on an
experimental basis. An important clinical study, however,
suggested that increased numbers of TAMs in classical
Hodgkin’s lymphoma correlated with resistance to chemo-
therapy, as well as poor patient survival (Steidl et al., 2010).
Recently, a clinical correlation has been made between
the presence of CD68/163þ macrophages in the involved
skin of MF patients and patient prognosis, suggesting that TAMs
may have a significant role in MF pathogenesis (Sugaya et al.,
2012).
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HLA DRþ macrophages have long been observed to be
uniformly present in MF lesions (Ralfkiaer et al., 1985), and
Sugaya et al. (2012) and Wu et al. (2011) have noted the
presence of CD68þ and CD163þ macrophages in MF skin
lesions. A true murine model of CTCL has yet to be established
because the development of skin T-cell lymphomas in mice is
exceedingly rare in contrast to humans, horses, or dogs. Thus,
the precise role of macrophages in the development of MF
lesions has been difficult to discern experimentally. Recently,
we have developed an inflammation-dependent murine
model of T-cell lymphoma development in skin that relies
on skin inoculation of MBL2 T lymphoma cell line and
subsequent stimulation of the skin with one topical
application of the contact sensitizer DNFB (Claman, 1976,
Wu et al., 2011). In this model, the development of tumors is
critically dependent on the application of DNFB, which
triggers IL1b cleavage and activation. Of note, depletion of
macrophages using clodronate-loaded liposomes around the
time of MBL2 inoculation (and DNFB stimulation) blocked the
establishment of tumors (Wu et al., 2011), suggesting an active
role for macrophages or their products in stimulating tumor
formation in this model.
Herein, we demonstrate that xenografted human Hut78
CTCL cells develop tumors in immunodeficient mice,
but that tumor development is blocked by depletion of
macrophages. Depletion of macrophages was associated with
the reduction of angiogenesis and lymphangiogenesis, as
well as loss of signal transducer and activator of transcription
(STAT)3 activation. These data, in conjunction with the
further use of our MBL2 tumor model, provide insights to
the downstream activities that are promoted by macrophages
within skin T-cell lymphoma and provide a rationale for
targeting macrophages in the treatment of MF and other
CTCLs.
RESULTS
MF lesions show increased mRNA expression of
macrophage-associated cytokines and markers
To gain insight regarding the inflammatory tumor microenvir-
onment in MF lesions, we performed array-based PCR analysis
on archived samples of skin lesions from a pooled cohort of 12
patients diagnosed with MF that included patch, plaque, and
tumor stages. Gene expression in these samples was com-
pared with that of normal skin. Interestingly, we observed
enhanced expression of a subset of macrophage-related
cytokines, chemokines, and associated receptors (Figure 1a).
CCL1, e.g., has been associated with maintenance of
M2-like macrophage properties (Asai et al., 2012), and CCL4
is known to promote recruitment of monocytes and macro-
phages via CCR5. CD163 mRNA expression was shown
to be increased in MF lesions (Figure 1b), was increased
in plaque (versus patch disease), and was easily detected
in tissue samples of MF by immunostaining (Figure 1c).
Thus, macrophage-associated cytokines and chemokines were
upregulated in MF skin lesions, and M2-like macrophage
numbers (as suggested by CD163 expression) appeared
to be increased in clinically thicker plaques compared with
patches.
Depletion of macrophages suppresses tumor growth in a murine
xenograft CTCL model
To date, there are no experimental data that demonstrate the
positive relationship between macrophage presence and
tumor development in human CTCLs. To address this ques-
tion, we used the well-known human CTCL T-cell line known
as Hut78, which will form tumors in immunocompromised
mice in a xenograft model. Hut78 cells were subcutaneously
xenografted into the flank of NSG, the immunocompromised
mice that lacked B, T, and natural killer cells. These mice,
however, still possess neutrophils and some other innate
immune cell populations, including macrophages. Tumor
implantation on day 0 was followed by subcutaneous injec-
tion of clodronate-containing liposomes (clo-liposomes) on
days 3, 5, 9, and 12 (Figure 2a). Upon analysis on day 21,
mice treated with clo-liposomes had a much smaller average
tumor size (35 mm2) compared with phosphate-buffered
saline (PBS)–liposome-treated mice (125 mm2, Po0.0001)
(Figure 2b). Histologically, the PBS–liposome-treated group
showed dense tumor cellularity, whereas clo-liposome-treated
mice did not show as much tumor formation (Figure 2c and d).
Thus, depletion of Hut78 TAMs with clo-liposomes leads to
reduced tumor growth in a human xenograft model of CTCL.
Macrophages show an M2-like phenotype in a mouse CTCL
tumor model
Immunostaining showed that there are abundant F4/80þ
macrophages in Hut78 tumors in mice (Figure 3a). To
determine the phenotype of macrophages within Hut78
tumors, we isolated tumors, prepared cell suspensions, and
isolated macrophages by F4/80 antibody staining coupled
with flow cytometric sorting. Recovery of macrophages from
PBS–liposome-treated tumors and expression phenotype by
reverse transcriptase–PCR revealed that the tumor macro-
phages expressed high levels of M2-like macrophage-asso-
ciated genes (Martinez et al., 2009) including arginase 1,
transforming growth factor-b1, and the immunosuppressive
cytokine IL-10 (Figure 3b).
Clodronate treatment leads to reduced macrophage numbers,
as well as lymphatic and endothelial cell markers in vivo
M2-like macrophages have been associated with tumorigenesis,
invasion, and metastasis (Mantovani et al., 2008). To determine
the effects of clodronate treatment on neovascularization and
macrophage depletion, we assessed the expression of several
well-characterized markers for immune, lymphatic, and vascu-
lar cells within the tumor microenvironment. Tumors were
harvested from mice implanted with Hut78 cells and treated
as described previously with either clo- or PBS-containing
liposomes. After harvesting tumors, we counted the number of
cells in each group that expressed F4/80, an adhesion protein
expressed on the surface of macrophages. Of note, significantly
fewer F4/80þ cells were seen in the clodronate-treated group,
which indicated that the macrophages were depleted in mice
treated with clo-liposomes. Quantification of F4/80þ
fluorescence intensity revealed an approximately 99.8%
decrease in F4/80þ cells in the clo-liposome-treated group
versus the control group (Figure 4).
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To evaluate the effects of clo-liposome treatment on vascular
and lymphatic formation within tumors, we stained tumors with
CD31 and podoplanin antibodies, respectively. There was a
significant decrease in signal from both lymphatic and blood
vascular vessels in clo-containing liposome-treated mice in
comparison with PBS–liposome-treated animals, suggesting that
blood and lymphatic vessels were decreased in tumors follow-
ing macrophage depletion (Figure 4). Interestingly, pSTAT3, a
proposed marker of the M2-like macrophage subpopulation
(Fujiwara et al., 2011, Sica and Mantovani, 2012), was also
decreased. These data indicate that macrophage depletion
potentially has a critical role in halting tumor development by
downregulating key activation pathways such as STAT3 and
affecting the ability of the tumor microenvironment to support
angiogenesis and lymphangiogenesis.
In vitro culture with clo-containing liposomes leads to significant
M2 macrophage cell death
Although the effects of clo-containing liposome treatment on
established tumor growth were evident in vivo, questions
remained as to whether or not its mechanism of action was
strictly restricted to macrophage depletion. To determine
whether clo-liposomes had any direct effects on malignant
T cells, 5105 Hut78 or M2-cultured macrophage cells
were exposed in vitro to clo-liposomes or PBS-containing
liposomes at a concentration of 1%. After 3 days in culture,
M2 macrophages showed up to 90% decrease in viability,
whereas survival of Hut78 cells was unaffected by clo-
liposomes (Figure 5a and b). Thus, it is unlikely that M2
macrophages reduce tumor formation by directly killing
neoplastic Hut78 T cells.
Treatment of established MBL2 tumors with localized
clo-containing liposome injection inhibits tumor growth in a
syngeneic model of CTCL
We have previously shown that clo-liposomes prevent the
development of MBL2 T-cell lymphomas in skin following
stimulation with the contact sensitizer DNFB (Wu et al.,
2011). In those experiments, mouse skin was depleted
of macrophages before implantation of tumor cells and
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Figure 1. A high concentration of macrophages exists in the cutaneous T-cell lymphoma (CTCL) microenvironment. (a) PCR array was run individually for
twelve mycosis fungoide (MF) samples from Medical College of Wisconsin (MCW), and gene expression was analyzed by pooling and averaging values from all
patients. Figure shows all genes with upregulation (44-fold versus normal skin). (b) Reverse transcriptase–PCR (RT–PCR) for CD163 expression in the MF
cohort from University of British Columbia demonstrates fold change of the mean level of CD163 in normal skin (n¼ 3), patch-stage MF (n¼9), plaque-stage
MF (n¼ 16), and tumor-stage MF (n¼ 1). (c) Immunofluorescent staining shows the presence of macrophages by using anti-CD163 (green) and T cells (including
both malignant and reactive T cells) by using anti-CD3 (red). White dotted line indicates the border of the epidermis and dermis. Bar¼100mm.
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subsequent topical application of DNFB to induce tumors.
Herein, to determine whether clo-liposomes could treat
established MBL2-DNFB tumors, we waited 5 days after
MBL2 inoculation and DNFB treatment before treatment
with clo-liposomes. Microscopic examination showed tumor
formation in the ears (data not shown), and ear thickness
during the course of the experiment noted thickening (over
that measured at baseline) of the skin by day 5. The skin was
injected subcutaneously at days 5 and 7 with clo-liposomes
or PBS-containing liposomes. On day 12, mice were killed,
and ears were harvested. Significant differences were seen
between clodronate treatment and control groups on day 11
(Po0.001), with ear thicknesses of 0.99 mm and 1.97 mm,
respectively. No significant change in tumor size was noted
between day 7 and day 11 in the clo-liposome-treated group,
whereas tumor growth was readily identified in PBS–
liposome-treated mice (Figure 6). When viewed at scanning
magnification in histological sections, MBL2 tumors were
reduced in size in the clo-liposome-treated tumors (Figure 6).
In light of these data, we conclude that macrophages are
critical for continued tumor growth in our syngeneic murine
model of CTCL.
DISCUSSION
Herein, we demonstrate that xenografted human CTCL cells
(Hut78) form large tumors in the skin of immunocompromised
mice following subcutaneous injection. Treatment with clo-
liposomes markedly decreased the numbers of F4/80þ macro-
phages, as well as reduced the presence of podoplaninþ
lymphatic vessels and CD31þ blood vessels, suggesting that
essential downstream protumorigenic events such as lymphan-
giogenesis and angiogenesis are hindered by the lack of
macrophages. Characterization of tumor-infiltrating macro-
phages from Hut78 tumors indicates that these macrophages
have an M2-like phenotype that is characteristic of TAMs.
Others have shown that TAMs are present in many solid
cancers and promote tumorigenesis, invasion, and possibly
metastasis (Mantovani et al., 2008). Tumor cells produce
chemokines (e.g., CCL5) that attract macrophage precursors
and cytokines (e.g., CSF-1 and IL-4) that promote induction
and survival of M2-like macrophages (Hanahan and
Weinberg, 2011). Of note, both lymphatic and vascular
angiogenesis are suppressed in mice treated with clo-
liposomes (Figure 4). Clo-liposome treatment, however, does
not directly affect either lymphatic or vascular vessel numbers
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Figure 2. Clodronate-containing liposomes decreased tumor growth in NSG mice. (a) Hut78 cells were implanted in flank skin of NSG mice on day 0.
Clodronate or phosphate-buffered saline (PBS) liposomes were administered twice a week for two weeks, i.e., on days 3, 5, 9, and 12. (b) A significant decrease in
tumor size was noted (Po0.0001, n¼ 5) in the clodronate treatment group, when compared with control. The experiments were repeated three times. (c, d) Tumor
tissue sections with hematoxylin and eosin (H&E) staining from Clo-liposome- and PBS–liposome-treated groups are shown grossly (c, bar¼ 10 mm) and
microscopically (d, bar¼100mm) (dense, blue staining area corresponds to tumor formation).
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(Supplementary Figure S1 online). Our data suggest that
depletion of TAMs, which are known to produce proangio-
genic factors, is a more likely reason for the reduced
angiogenesis found in clo-liposome-treated tumors.
We also demonstrate that pSTAT3, a key mediator of tumor-
promoting inflammation, is downregulated following clo-
liposome treatment. STAT3 has been reported to be constitu-
tively activated in CTCL in vivo and may function to prevent
apoptosis (Sommer et al., 2004). In addition, STAT3 mediates
the expression of IL17A, a cytokine whose expression appears
to be linked to poor prognosis in profiling data from large
CTCL patient cohorts (Litvinov et al., 2010). Thus, key
tumorigenic systems such as angiogenesis and STAT3 acti-
vation are suppressed in tumor tissue following depletion of
macrophages.
Clinical data from this and others (Sugaya et al., 2012)
demonstrate that substantial numbers of CD68þ and CD163þ
macrophages are present in human CTCL lesions. Sugaya et al.
(2012) demonstrated that the presence of increased numbers
of macrophages in MF lesions were associated with poor
survival in a Japanese patient population, while our data
suggest that patients with thicker, more indurated plaque
lesions expressed higher levels of CD163 in the skin than
patients with thinner patch-stage lesions (Figure 1). Both
results suggest that increased clinical severity is associated
with greater numbers of macrophages in CTCL skin lesions.
Although CTCLs, including MF, are considered non-Hodgkin’s
lymphoma, emerging data from Hodgkin’s lymphoma disease
cohorts reveal that the presence of macrophage markers
portend poor prognosis (Steidl et al., 2010, Sanchez-
Espiridion et al., 2012) and resistance to treatment (Steidl
et al., 2010). In aggregate, these clinical data support the
concept that the presence of large numbers of macrophages in
lymphoma tissues in MF may be clinically relevant and
helpful in assessing prognosis in these patients.
Although the presence of macrophages in MF skin tissue is
clearly demonstrable, their relevance to tumor progression
cannot be directly inferred from patient data alone. Our prior
results using our DNFB-triggered MBL2 T-cell lymphoma
model showed that depletion of macrophages before DNFB
stimulation largely prevented tumors from growing, but we felt
it was critical to demonstrate that the continued growth of
established MBL2 T-cell lymphomas can be slowed by
macrophage depletion. As shown in Figure 6, treatment as
late as day 5 after DNFB application with clo-liposomes
reduced tumor development. Moreover, we demonstrate that
Hut78 cells derived from a CTCL patient are also unable to
form tumors in immunocompromised mice following clo-
liposome treatment, validating our MBL2 model and showing
that the clo-liposome treatment can be considered in the
context of human CTCL cells.
There are several limitations to our study. First, regarding
our human expression data suggesting that Th1 and Th2
cytokines can both be observed (Figure 1a), we note that
these results were taken from a relatively small, pooled cohort
of MF patients that may reflect the heterogenous nature of the
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Figure 3. M2-like macrophages are abundant within the tumor microenvironment of cutaneous T-cell lymphoma (CTCL) mouse model. (a) In total, 1106
Hut78 cells were injected into the subcutaneous area of flank skin in NSG mice. Tumor formed in 3 weeks. Images for immunostaining on tumor sections
are displayed after staining with anti-F4/80 (left) and isotype control (rat IgG2a) (right). Bar¼ 100mm. (b) Macrophage phenotypes were analyzed by reverse
transcriptase–PCR (RT–PCR) for F4/80-positive macrophages sorted from tumor suspension cells (tumor M2). Macrophages recovered from the spleens of normal
(NS) or tumor-bearing mice (TS) were used as controls.
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disease. Subsequent analysis with a larger cohort of patients
showed a trend in which early MF patients showed higher Th1
(i.e., CXCL9-11) and lower Th2 (i.e., IL-10) cytokine expres-
sion compared with patients with more advanced disease
(data not shown). These results, along with our human data
suggesting that macrophages are more abundant in plaque
versus patch skin, support data from other studies (Assudulah
et al., 1996, Sugaya et al., 2012). Second, other phagocytic
cells such as antigen-presenting cells of the skin (i.e.,
Langerhans cells and dermal dendritic cells) can potentially
take up liposomes. Thus, we cannot completely exclude their
influence on tumorigenesis. However, other CTCL studies
suggest that dendritic cells have a significant role in
generating antitumor immunity in CTCLs (Girardi et al.,
2002, Geskin et al., 2004) in addition to potentially
stimulating CTCL tumorigenesis (Berger et al., 2002). Recent
data using clodronate depletion strongly suggest that
macrophages inhibit effective antitumor responses to
lymphoma cells in vaccination studies (Honeychurch et al.,
2013). Elegant experimental models (Bennett et al., 2005,
Kissenpfennig et al., 2005) that can selectively deplete specific
dendritic cell populations (e.g., Langerhans cells) may be
excellent vehicles to later test the role of dendritic cells in
tumor promotion in the MBL2 and Hut78 models.
Nearly all current lymphoma treatments are targeted at the
malignant T or B cells themselves. Rituximab (anti-CD20) and
brentuximab vedotin (anti-CD30 antibody linked to a cellular
toxin) are examples of such therapies, which can be specific
and highly effective (Rehwald et al., 2003, Bander et al.,
2012). Our results, however, clearly suggest that modulation
of the immune environment can result in suppression of tumor
growth that is independent of the ability of the drug to directly
kill the malignant cells. Thus, immunotherapy strategies that
target non-lymphoma cells deserve further consideration.
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Figure 4. Depletion of macrophages was associated with reduced lymphatic, endothelial cell markers, and phosph-signal transducer and activator of
transcription (STAT)3 signals. (a) Immunofluorescent (IF) staining for tumor tissues from mice treated with clodronate and phosphate-buffered saline (PBS),
respectively. Antibodies for F4/80, podoplanin, CD31, and phospho (p)-STAT3 were used. Tissues were co-stained with 4’,6-diamidino-2-phenylindole (DAPI)
(blue). Bar¼100 mm. (b) Image analysis was performed with the Image J software.
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MATERIALS AND METHODS
Collection of human samples
Formalin-fixed, paraffin-embedded skin biopsy samples from 12 MF
patients from Medical College of Wisconsin (MCW) were staged
according to clinical records and evaluated for disease severity
including epidermotropism and epidermal hyperplasia by patholo-
gists in a blinded manner (Supplementary Table S1 online). Three
healthy skin controls were collected from excised redundant skin
from patients undergoing plastic surgery. In addition, another larger
cohort of RNA samples from 26 human MF patients (9 from patch-,
16 from plaque-, and 1 from tumor-stage MF) and three normal-skin
samples were provided by Dr Youwen Zhou (University of British
Columbia, Canada) (Zhang et al., 2012). Institutional review board
approval was obtained from the respective review committees at the
MCW or the University of Vancouver, British Columbia, for the use of
previously archived human tissue in a blinded, anonymous manner.
Specimens were collected initially for clinical diagnostic purposes
and the samples were used in accordance with Helsinki guidelines.
Cultured cells
Hut78 cells are a CTCL cell line purchased from ATCC (Manassas,
VA). Cells were cultured in ATCC-formulated Iscove’s Modified
Dulbecco’s Medium with 20% heat-inactivated fetal bovine serum.
The MBL2 cell line (courtesy Dr Mark Udey, National Cancer
Institute) was derived from Moloney MuLV-induced T-cell lymphoma
in C57BL/6 mice (van Hall et al., 2000). MBL2 cells were cultured in
DMEM (Invitrogen, Waltham, MA) with 10% fetal bovine serum.
Mice
The NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice and C57BL/6
mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
All animal experiments were carried out at MCW in accordance with
the guidelines and approval of the Institutional Animal Care and
Usage Committee.
PCR array and quantitative real-time PCR
RT2 Profiler PCR Arrays (SA Biosciences, Valenica, CA) were used for
human cytokine/chemokine receptor expression analysis. Briefly,
total RNA was extracted using the RNeasy formalin-fixed, paraffin-
embedded kit (Qiagen, Valencia, CA). A mesure of 100 ng of RNA
from each sample was used for converting into cDNA with the RT2
PreAMP cDNA Synthesis Kit (SA Biosciences). Each cDNA sample
was used for PCR array analysis, with real-time PCR performed on a
StepOne Plus Real-time PCR system (Applied Biosystem, Carlsbad,
CA). Raw threshold cycle data were uploaded to web-based PCR
array (SA Biosciences) analysis software for comparison between MF
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Hut78 cells were cultured with 1% phosphate-buffered saline (PBS) liposomes or 1% clodronate liposomes for three days and then analyzed by (a) phase-light
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patients and normal-skin controls. Regular quantitative real-time PCR
was performed for CD163 expression level in MF samples through
designing primers for hCD163 and glyceraldehyde 3-phosphate
dehydrogenase , the endogenous control (primers for CD163: 50-
caacttgagtcccttcacca-30 and 50-ccactcctcctggactttca-30; primers for
glyceraldehyde 3-phosphate dehydrogenase: 50-acccactcctc-
cacctttga-30 and 50-cataccaggaaatgagcttgacaa-30).
CTCL tumor model and treatment with clodronate liposomes
For establishing the CTCL mouse model in immunodeficient
NSG mice, we injected subcutaneously 200ml of Hut78 cells in
PBS at a concentration of 5 106 ml 1, i.e., 1 106 per mouse,
under the mouse flank skin. For clodronate treatment, we injected
200ml of clodronate lipsomes (provided by Dr Nico van Rooijen,
Foundation Clodronate Liposomes, The Netherlands) around the
tumor implantation sites twice a week after tumor inoculation for
2 weeks; the exact days of administration of clo-liposomes are
described in the results section. PBS-containing liposomes were used
as control. Tumor growth was measured twice a week using calipers,
and mice were killed after 3 weeks, as previously described
(Wu et al., 2011).
Immunofluorescent staining
Tumor tissues from the CTCL model were isolated and cut into two
halves. One half was fixed in 10% formalin followed by hematoxylin
and eosin staining processing via the MCW histology core. The other
half was fast-frozen, cut into 6-mm sections, fixed in cold acetone, and
blocked in 3% dry milk–PBS (Bio-Rad, Hercules, CA) before 4 1C
overnight incubation with primary antibodies anti-F4/80 (eBiosciences,
San Diego, CA), anti-CD31 (Biolegend, San Diego, CA), anti-podo-
planin (R&D, Minneapolis, MN), anti-EGFR3, and anti-phospho-STAT3
(BD Bioscience, San Jose, CA). Goat anti-rat IgG2a Ab conjugated with
AlexaFluor 488 and Goat anti-mouse IgG2b conjugated with Alexa-
Fluor 568 (Invitrogen, San Jose, CA) were used for secondary detection.
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Figure 6. Treatment of established skin T-cell lymphoma with clodronate liposomes in immunocompetent mice. MBL2 cells were implanted in ears of
C57BL6 mice, followed immediately by topical application of DNFB, on day 0. Clodronate or phosphate-buffered saline (PBS) control was administered by
intradermal injection on days 5 and 7. Mice were killed and ears were examined for tumor formation on day 12. (a) Microscopic examination of ears
implanted with tumor cells, treated with either clodronate or PBS-containing lipsomes. Normal mouse ear was processed in parallel as a control. Bar¼ 100mm.
(b) Mouse ear thickness, a surrogate marker of tumor growth, was evaluated at various time points (n¼5 per group).
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Macrophage isolation and macrophage phenotype identification
Implanted CTCL tumors removed from killed mice were cut into small
pieces and put into 10-fold volume of digestion medium (DMEM
containing 10% fetal bovine serum, 0.1% collagenase, 0.05%
DNaseI) with shaking at 37 1C for 1 hour. Further, the digested tumor
tissue was filtered through a 70-mM strainer followed by spinning for
single-cell collection. After washing with PBS, cells were stained with
antibody for macrophage marker (antigen-presenting cell-labeled anti-
F4/80, eBiosciences) and cell-sorted on FACS Aria (Becton-Dicken-
son, Franklin Lakes, NJ). Total RNA was extracted from isolated
F4/80-positive macrophages for reverse transcriptase–PCR analysis.
In vitro M2 macrophage induction and clodronate treatment
Bone marrow cells from C57BL/6 mice were differentiated in vitro
into M2 macrophages with IL-4 and IL-13. To determine the direct
effects of clodronate liposomes on cells in vitro, cultured M2
macrophages and Hut78 tumor cells were exposed to clodronate or
PBS-containing liposomes at a concentration of 1%. After three days
of incubation, cells were stained with trypan blue for enumeration of
live cells.
Syngeneic skin T-cell lymphoma model and clodronate treatment
According to our previous work (Wu et al., 2011), we injected 20ml
of PBS containing 4 105 MBL2 cells into the subcutaneous area
in ear skin of anesthetized mice using a 27-gauge needle followed
by topical application of 10ml of DNFB over the injection site.
Aggressive lymphoma usually forms within 2 weeks after inoculation.
For treatment, we administered intradermal injection of 20ml of
clodronate liposomes on days 5 and 7.
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